Blood NAD+: what the evidence supports and Nicotinamide Riboside
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Outcome map
Blood NAD+: what the evidence supports
2 graded interventions for blood nad+, ranked by strength of evidence.
Grade A2 graded outcomesrevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Compound or practice
Nicotinamide Riboside
The better-studied NAD+ precursor — reliably raises NAD+, still short on hard human outcomes.
Grade C2 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
No outcome has the same name in both entries. They may still overlap under different wording — read the two lists below.
Graded only in Blood NAD+: what the evidence supports
- Nicotinamide Riboside Moderate effectEvidence grade A
- NMN Moderate effectEvidence grade B
Graded only in Nicotinamide Riboside
- Blood NAD+ Moderate effectEvidence grade A
- Physical / metabolic function Small effectEvidence grade C
What each entry says about the other
- Blood NAD+: what the evidence supports’s entry · Goes with: Grade A
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.